10-Q: Kestra Medical Technologies Reports Strong Revenue Growth, Continued Losses

Kestra Medical Technologies announced significant revenue and gross profit increases in its latest quarterly report, driven by patient growth, while also reporting continued net losses and ongoing efforts to address internal control weaknesses.

Summary

• Revenue for the three months ended January 31, 2026, increased by 63% to $24.6 million, and for the nine months, it rose 56% to $66.5 million, primarily due to a 58% and 55% increase in patients using products, respectively.
• Gross profit for the three months increased by 97% to $12.9 million, and for the nine months, it doubled to $33.2 million, driven by revenue growth and a 14-17% decrease in cost of revenues per patient.
• Net loss for the three months increased to $34.2 million from $21.8 million, and for the nine months, it grew to $92.8 million from $62.7 million.
• Net loss per share improved to $(0.61) for the three months and $(1.76) for the nine months, compared to $(1.25) and $(3.56) in the prior year periods, respectively, due to increased shares outstanding.
• Cash and cash equivalents stood at $291.3 million as of January 31, 2026, up from $237.6 million on April 30, 2025, bolstered by a $149.3 million public offering in December 2025.
• The company identified material weaknesses in its internal control over financial reporting, including insufficient resources in accounting, finance, and IT, and ineffective controls over complex transactions and IT general controls.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed report. While strong revenue and gross profit growth indicate successful market penetration and operational efficiency, the increasing net losses and identified material weaknesses in internal controls present significant concerns that temper the overall positive momentum.

Positives

• Strong revenue growth of 63% for the quarter and 56% for the nine months, indicating increasing market adoption of the ASSURE WCD.
• Gross profit nearly doubled for both the three and nine-month periods, demonstrating improved operational efficiency and cost management per patient.
• Cost of revenues per patient decreased by 14% for the quarter and 17% for the nine months, attributed to better utilization of medical equipment, lower disposable costs from volume, and manufacturing improvements.
• The estimated useful life of medical rental equipment components (WCD monitor and battery charger) was extended from 2-8 years to 2-15 years, reducing depreciation expense by $705k for the quarter.
• Significant cash balance of $291.3 million provides strong liquidity, supported by a recent $149.3 million public offering.
• Strategic collaboration with Biobeat Technologies, Ltd. and a $5.0 million equity investment aim to expand diagnostic insights and enhance the Cardiac Recovery System platform.
• Net loss per share improved despite increased net loss, reflecting the impact of capital raises and increased shares outstanding.

Negatives

• Net loss increased to $34.2 million for the quarter and $92.8 million for the nine months, indicating continued unprofitability.
• Operating expenses significantly increased by 76% for the quarter and 72% for the nine months, primarily due to higher personnel expenses, share-based compensation, and costs associated with being a public company.
• Cash used in operating activities increased to $63.0 million for the nine months, up from $53.6 million in the prior year, reflecting a higher cash burn from operations.
• Accumulated deficit grew to $613.0 million, highlighting substantial historical losses.
• Identified material weaknesses in internal control over financial reporting, indicating deficiencies in financial reporting processes and IT controls.

Risks

• Ability to continue expanding commercialization of the ASSURE WCD and future product candidates.
• Maintaining existing regulatory approvals and obtaining new ones for market expansion or new products.
• Uncertainty regarding the rate and degree of market acceptance of products.
• Dependence on the availability of reimbursement from third-party payors (Medicare, Medicaid, private payors).
• Challenges in scaling manufacturing, securing timely component supplies, and effectively managing inventory and distribution.
• Difficulty in hiring and retaining qualified personnel, including senior management and sales professionals.
• Reliance on estimates for total addressable market and near-term achievable market.
• Uncertainty in the timing or likelihood of regulatory filings and approvals/clearances.
• Risks associated with growth plans, including entering new markets.
• Ability to establish and maintain intellectual property protection or defend against infringement claims.
• Uncertainty regarding the progress, timing, costs, and results of clinical trials.
• Potential impact of changes and developments in the regulatory landscape.
• Vulnerability to changes in financial performance and market trends.
• Increased expenses and compliance burden associated with operating as a public company.
• Competitive pressures and industry changes.
• Risk of not obtaining sufficient additional funding on acceptable terms, which could materially and adversely affect the business.
• Material weaknesses in internal control over financial reporting could lead to undetected material misstatements in financial statements.

Future Outlook

The company expects revenue to continue increasing with patient growth and anticipates research and development expenses to decrease as a percentage of revenue. Selling, general, and administrative expenses are projected to increase in absolute terms due to headcount growth but decrease as a percentage of revenue. Management believes existing cash and cash equivalents, along with cash generated from revenue, will be sufficient to fund operating and capital needs for at least the next 12 months, but acknowledges the potential need for additional funding for growth plans.

Management Comments

• We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.
• We believe the ASSURE WCD offers significant clinical and functional advantages, including greater patient compliance as a result of a major reduction in false alarms, enhanced comfort and improved wearability.
• We believe our Cardiac Recovery System platform has the potential to disrupt the large existing market and grow the under-penetrated addressable market.
• Based on our current operating plan, we believe that our existing cash and cash equivalents and cash generated from revenue transactions with customers will be sufficient to fund our operating and capital needs for at least the next 12 months.
• Our ability to maintain qualified and adequate resources to support the Company and our projected growth will be a critical component of our internal control environment.

Industry Context

StockSavvy.ai notes that Kestra Medical Technologies operates in the growing wearable medical device market, specifically targeting cardiovascular disease with its ASSURE WCD. The company's focus on integrating monitoring, therapeutic treatment, digital health, and patient support services aligns with broader industry trends towards comprehensive, connected healthcare solutions. The significant revenue growth suggests strong demand for its WCD product, positioning it as a notable player in a market segment that benefits from established reimbursement codes and an under-penetrated addressable market.

Corporate Governance

Legal Proceedings

• The company is from time to time a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of business.
• Management does not expect any pending legal proceedings to have a material adverse effect on its results of operations, financial position, or cash flows.

Stakeholder Impact

• Shareholders: Experienced dilution from the public offering but also benefited from increased liquidity and a stronger cash position. Continued net losses and internal control weaknesses pose risks to future share value.
• Employees: Increased headcount to support commercial growth, and the approval of the 2025 Employee Stock Purchase Plan (ESPP) provides an additional incentive.
• Customers (Patients): Increased number of patients using the ASSURE WCD, indicating successful product adoption and potential for improved patient outcomes in cardiovascular disease.
• Creditors: The company is in compliance with all financial covenants of its Term Loan 2024 as of January 31, 2026, and has a strong cash position to meet obligations.

Next Steps

• Continue to expand the commercialization of the ASSURE WCD and the Cardiac Recovery System platform.
• Invest in research and development activities for new products and services, and enhance existing ones.
• Conduct clinical trials as necessary and prepare new products/services for commercialization.
• Increase the size of the commercial team to market products in the United States.
• Remediate identified material weaknesses in internal control over financial reporting by hiring additional personnel, engaging third parties, designing new controls, and enhancing IT governance processes.
• Potentially seek additional funding through future equity and debt financings to support growth plans.

Key Dates

Recommendation

While Kestra Medical Technologies demonstrates impressive revenue and gross profit growth, indicating strong market acceptance for its ASSURE WCD, the persistent and increasing net losses, coupled with identified material weaknesses in internal financial controls, present significant risks. The recent capital raise provides substantial liquidity for the near term, supporting continued investment in growth and remediation efforts. However, until there is clear evidence of a path to profitability and successful resolution of the internal control issues, a 'hold' recommendation is appropriate, advising investors to monitor progress closely without adding to or divesting from their positions.

Keywords

Wearable Cardioverter Defibrillator, WCD, Cardiac Recovery System, Medical Device, Cardiovascular Disease, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss, Internal Controls, Biobeat, Public Offering, Healthcare Technology, KMTS